文献速递主动脉疾病

真实世界多中心LIFE注册研究:激光原位开窗腔内修复复杂胸腹及近内脏动脉主动脉病变的结果

Outcomes from the real-world multicenter laser in situ fenestrated endovascular repair (LIFE) registry for complex thoracoabdominal and pararenovisceral aortic pathology.
PubMed 文献 · J Vasc Surg · 2026-09-07

基于多中心LIFE注册数据库,回顾性分析2017-2022年9家中心210例接受激光原位开窗腔内修复(LIFE)的胸腹及近内脏动脉主动脉病变患者。技术成功率95%,30天死亡率8%,症状性/破裂病变患者死亡率显著更高(P<.0001)。LIFE在无商业解决方案时是可行选择,但再干预需求高于预期。

要点

  • LIFE技术成功率达95%,30天死亡率为8%,症状性/破裂病变患者死亡风险显著增高。
  • 中远期再干预率21%,主动脉支架再干预需求高于预期,可能与学习曲线相关。
  • 无症状患者20个月生存率(82% vs 63%)和桥接支架免再干预率(88% vs 77%)均更优。

核心结论

  • LIFE注册研究是迄今最大规模的多中心LIFE技术经验,围手术期和中期结果在包含较高比例症状性/破裂病变的队列中合理。
  • 主动脉支架再干预需求高于预期,可能与技术学习曲线有关,且高于医师改良支架或开窗/分支腔内修复的报道。
  • LIFE修复在无商业可用解决方案时是可行治疗选择,尤其对症状性或破裂的胸腹及近内脏主动脉病变患者,但需长期评估耐久性和再干预率。

研究设计与样本

  • 回顾性多中心注册数据库研究,纳入2017-2022年9家高容量中心所有接受LIFE治疗的胸腹及近内脏动脉主动脉瘤患者,共210例。
  • 采用描述性统计和Kaplan-Meier分析,主要结局为技术成功和目标血管不稳定,次要结局包括死亡、卒中、截瘫和再干预。

主要发现

  • 210例患者平均年龄72.3岁,27%女性,83%白人;既往主动脉修复占55%,症状性/破裂病变占39%。
  • 30天死亡17例(8%),其中症状性/破裂病变15例死亡,无症状患者2例死亡(P < .0001)。
  • 技术成功率95%;卒中6例(2.9%),永久性截瘫4例(2%)。
  • 平均随访9个月(范围1-35),额外死亡12例(5.7%),其中动脉瘤相关4例(2%)。
  • Kaplan-Meier 36个月总生存率70%,24个月桥接支架免再干预率80%(标准误均<10%)。

关键数值与推荐

  • 近端锚定区:Zone 2占1%,Zone 3占5%,Zone 4占10%,Zone 5占34%,Zone 6占14%,Zone 7占16%,Zone 8占17%。
  • 共 incorporated 529根目标血管,平均每例2.5根;1根占18%,2根占26%,3根占29%,4根占24%,未报告占3%。
  • 总体再干预64例(21%),额外主动脉支架21例(10%),桥接支架再干预24根目标血管(4.5%),弹簧圈栓塞4例(2%),其他手术3例(1.4%)。
  • 无症状患者20个月总生存率82% vs 症状性/破裂63%(P = .0007),21个月桥接支架免再干预率88% vs 77%(P = .0005),标准误<10%。

临床怎么用

  • LIFE可作为无商业可用支架时复杂胸腹及近内脏主动脉病变的可行治疗选择,尤其适用于症状性或破裂病例。
  • 需警惕较高的主动脉支架再干预需求,术后应加强影像随访监测。
  • 症状性/破裂病变患者围手术期死亡风险显著增高,术前应充分评估并告知风险。

局限性

  • 回顾性注册研究设计,存在选择偏倚和信息偏倚可能。
  • 平均随访仅9个月(范围1-35),长期耐久性数据有限。
  • 再干预率高于预期可能与技术学习曲线相关,各中心经验差异未详细分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Laser in situ fenestrated endovascular (LIFE) repair enables fenestrated endovascular aortic repair in complex and challenging cases, including urgent and emergency presentations and patients with prior aortic repairs. From the real-world multicenter LIFE registry, the results are reported for this unique approach for thoracoabdominal and pararenovisceral aortic aneurysm (TAAA/PAA) pathologies. METHODS: All patients (2017-2022) undergoing LIFE for thoracoabdominal and pararenovisceral aortic aneurysms were identified at nine high-volume institutions and were included in a retrospective multicenter registry database. Descriptive statistics and Kaplan-Meier analysis were used. The primary outcomes were technical success and target vessel instability. The secondary outcomes included mortality, stroke, paraplegia, and reintervention. RESULTS: This study included 210 patients undergoing LIFE (mean age, 72.3, 27% female, 83% White). The notable demographics included previous stroke in 14%, chronic obstructive pulmonary disease in 26%, renal insufficiency in 27% (dialysis in 3%), and previous aortic repair in 55% of patients. Indications for repair included fusiform aneurysm in 69%, type Ia endoleak in 21%, saccular aneurysm in 10%, and aortic dissection in 7%. Repair was performed for symptomatic/ruptured pathologies in 39% of patients. Overall, 30-day deaths occurred in 17 patients (8%), with 15 deaths in patients with symptomatic/ruptured pathologies and 2 deaths in asymptomatic patients (P < .0001). Proximal seals were achieved in Zone 2 (1%), Zone 3 (5%), Zone 4 (10%), Zone 5 (34%), Zone 6 (14%), Zone 7 (16%), and Zone 8 (17%). A total of 529 target vessels were incorporated (one vessel in 18%, two vessel in 26%, three vessel in 29%, four vessel in 24%, and NR in 3% of patients), with a mean of 2.5 target vessels per patient. The technical success rate for LIFE repair was 95%. Fifteen deaths occurred in 77 patients (19%) with symptomatic/ruptured pathologies. The results revealed stroke in six (2.9%) and permanent paraplegia in four patients (2%). At the mean follow-up of 9 months (range, 1-35), 12 additional deaths (5.7%) occurred, four of which were aneurysm-related (2%). Kaplan-Meier survival for the overall cohort at 36 months was 70%, with 80% freedom from bridging stent reintervention at 24 months (both standard error <10%). By group, asymptomatic patients had higher overall survival (82% vs 63%; P = .0007) at 20 months and freedom from bridging stent reintervention (88% vs 77%; P = .0005) at 21 months than patients with symptomatic/ruptured pathologies (standard error <10%). Overall reinterventions were performed in 64 patients (21%), with additional aortic stent graft in 21 patients (10%), bridging stent reintervention to 24 target vessels (4.5%), coil embolization in 4 patients for type II endoleak and to the false lumen of a dissection (2%), and other surgical procedures in 3 patients (1.4%). CONCLUSIONS: The LIFE registry represents the largest multicenter experience with the LIFE technique to date. The perioperative and mid-term outcomes are reasonable in a cohort with a significant proportion of patients with symptomatic/ruptured pathologies. There was a higher-than-expected need for aortic stent graft reinterventions, which may be related to the learning curve for the technique and is higher than described for physician-modified endografts or fenestrated/branched endovascular aneurysm repair. These data suggest that LIFE repair is a viable treatment option when no commercially available solution exists, particularly among patients presenting with symptomatic or ruptured thoracoabdominal and pararenovisceral aortic pathologies. The need for longer-term evaluation of the durability and reintervention rate is of paramount importance to fully assess the applicability of this technique.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Bath J, Alie-Cusson F, Han SM, et al. Outcomes from the real-world multicenter laser in situ fenestrated endovascular repair (LIFE) registry for complex thoracoabdominal and pararenovisceral aortic pathology. J Vasc Surg. 2026. PMID: 42705504. doi:10.1016/j.jvs.2026.07.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。